mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.
Science
; 384(6697): eadk0582, 2024 May 17.
Article
en En
| MEDLINE
| ID: mdl-38753770
ABSTRACT
Germline-targeting (GT) HIV vaccine strategies are predicated on deriving broadly neutralizing antibodies (bnAbs) through multiple boost immunogens. However, as the recruitment of memory B cells (MBCs) to germinal centers (GCs) is inefficient and may be derailed by serum antibody-induced epitope masking, driving further B cell receptor (BCR) modification in GC-experienced B cells after boosting poses a challenge. Using humanized immunoglobulin knockin mice, we found that GT protein trimer immunogen N332-GT5 could prime inferred-germline precursors to the V3-glycan-targeted bnAb BG18 and that B cells primed by N332-GT5 were effectively boosted by either of two novel protein immunogens designed to have minimum cross-reactivity with the off-target V1-binding responses. The delivery of the prime and boost immunogens as messenger RNA lipid nanoparticles (mRNA-LNPs) generated long-lasting GCs, somatic hypermutation, and affinity maturation and may be an effective tool in HIV vaccine development.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Anticuerpos Anti-VIH
/
VIH-1
/
Inmunización Secundaria
/
Vacunas contra el SIDA
/
Centro Germinal
/
Nanopartículas
/
Anticuerpos ampliamente neutralizantes
/
Vacunas de ARNm
Límite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Science
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos